Andrew W. Daman

Andrew W. Daman

Auto-generated profile, based on publicly available information

Andrew W. Daman

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
SOShannon K. Oda
Shannon K. Oda
KAKristin G. Anderson
Kristin G. Anderson
PRPranali Ravikumar
Pranali Ravikumar
PBPatrick Bonson
Patrick Bonson
NGNicolas M. Garcia
Nicolas M. Garcia
PGPhilip D. Greenberg
Philip D. Greenberg
Adoptive T cell therapy (ACT) with genetically modified T cells has shown impressive results against some hematologic cancers, but efficacy in solid tumors can be limited by restrictive tumor microenvironments (TMEs). For example, Fas ligand is commonly overexpressed in TMEs and induces apoptosis in tumor-infiltrating, Fas receptor–positive lymphocytes. We engineered immunomodulatory fusion proteins (IFPs) to enhance ACT efficacy, combining an inhibitory receptor ectodomain with a costimulatory endodomain to convert negative into positive signals. We developed a Fas-4-1BB IFP that replaces the Fas intracellular tail with costimulatory 4-1BB. Fas-4-1BB IFP-engineered murine T cells exhibited increased pro-survival signaling, proliferation, antitumor function, and altered metabolism in vitro. In vivo, Fas-4-1BB ACT eradicated leukemia and significantly improved survival in the aggressive KPC pancreatic cancer model. Fas-4-1BB IFP expression also enhanced primary human T cell function in vitro. Thus, Fas-4-1BB IFP expression is a novel strategy to improve multiple T cell functions and enhance ACT against solid tumors and hematologic malignancies.

30 November 2017 in Blood
Verified
Journal Article
Open access
PDF file
SOShannon K. Oda
Shannon K. Oda
ADAndrew W. Daman
Andrew W. Daman
NGNicolas M. Garcia
Nicolas M. Garcia
FWFelecia Wagener
Felecia Wagener
TSThomas M. Schmitt
Thomas M. Schmitt
PGPhilip D. Greenberg
Philip D. Greenberg
Key Points: IFPs can convert signals from inhibitory ligands into activating signals. Costimulation was most effectively achieved by engineering the IFP to promote the ability to localize in the immunological synapse.

18 October 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
DDDinesh Deochand
Dinesh Deochand
MDMarija Dacic
Marija Dacic
MBMichael Bale
Michael Bale
ADAndrew W. Daman
Andrew W. Daman
VCVidyanath Chaudhary
Vidyanath Chaudhary
IRInez Rogatsky
Inez Rogatsky
Macrophages adopt distinct phenotypes in response to environmental cues, with type-2 cytokine interleukin-4 promoting a tissue-repair homeostatic state (M2IL4). Glucocorticoids (GC), widely used anti-inflammatory therapeutics, reportedly impart a similar phenotype (M2GC), but how such disparate pathways may functionally converge is unknown. We show using integrative functional genomics that M2IL4 and M2GC transcriptomes share a striking overlap mirrored by a shift in chromatin landscape in both common and signal-specific gene subsets. This core homeostatic program is enacted by transcriptional effectors KLF4 and the glucocorticoid receptor, whose genome-wide occupancy and actions are integrated in a stimulus-specific manner by the nuclear receptor cofactor GRIP1. Indeed, many of the M2IL4:M2GC-shared transcriptomic changes were GRIP1-dependent. Consistently, GRIP1 loss attenuated phagocytic activity of both populations in vitro and macrophage tissue-repair properties in the murine colitis model in vivo. These findings provide a mechanistic framework for homeostatic macrophage programming by distinct signals, to better inform anti-inflammatory drug design.

9 August 2024 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
PSPedro Saavedra
Pedro Saavedra
ATAlissa J. Trzeciak
Alissa J. Trzeciak
ALAllie Lipshutz
Allie Lipshutz
ADAndrew W. Daman
Andrew W. Daman
AOAnya J. O’nEal
Anya J. O’nEal
JPJustin S. A. Perry
Justin S. A. Perry
The clearance of apoptotic cells, termed efferocytosis, is essential for tissue homeostasis and prevention of autoimmunity1. Although past studies have elucidated local molecular signals that regulate homeostatic efferocytosis in a tissue2,3, whether signals arising distally also regulate homeostatic efferocytosis remains elusive. Here, we show that large peritoneal macrophage (LPM) display impairs efferocytosis in broad-spectrum antibiotics (ABX)-treated, vancomycin-treated and germ-free mice in vivo, all of which have a depleted gut microbiota. Mechanistically, the microbiota-derived short-chain fatty acid butyrate directly boosts efferocytosis efficiency and capacity in mouse and human macrophages, and rescues ABX-induced LPM efferocytosis defects in vivo. Bulk messenger RNA sequencing of butyrate-treated macrophages in vitro and single-cell messenger RNA sequencing of LPMs isolated from ABX-treated and butyrate-rescued mice reveals regulation of efferocytosis-supportive transcriptional programmes. Specifically, we find that the efferocytosis receptor T cell immunoglobulin and mucin domain containing 4 (TIM-4, Timd4) is downregulated in LPMs of ABX-treated mice but rescued by oral butyrate. We show that TIM-4 is required for the butyrate-induced enhancement of LPM efferocytosis capacity and that LPM efferocytosis is impaired beyond withdrawal of ABX. ABX-treated mice exhibit significantly worse disease in a mouse model of lupus. Our results demonstrate that homeostatic efferocytosis relies on distal metabolic signals and suggest that defective homeostatic efferocytosis may explain the link between ABX use and inflammatory disease4,5,6,7.

23 July 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ADAndrew W. Daman
Andrew W. Daman
SJSteven Z. Josefowicz
Steven Z. Josefowicz
The three classes of interferons (IFNs) share the ability to inhibit viral replication, activating cell transcriptional programs that regulate both innate and adaptive responses to viral and intracellular bacterial challenge. Due to their unique potency in regulating viral replication, and their association with numerous autoimmune diseases, the tightly orchestrated transcriptional regulation of IFNs has long been a subject of intense investigation. The protective role of early robust IFN responses in the context of infection with SARS-CoV-2 has further underscored the relevance of these pathways. In this viewpoint, rather than focusing on the downstream effects of IFN signaling (which have been extensively reviewed elsewhere), we will summarize the historical and current understanding of the stepwise assembly and function of factors that regulate IFNβ enhancer activity (the “enhanceosome”) and highlight opportunities for deeper understanding of the transcriptional control of the ifnb gene.

15 July 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
CBCHRISTOPHER Bourne
CHRISTOPHER Bourne
SMSung Soo Mun
Sung Soo Mun
TDTao Dao
Tao Dao
ZAZita E. H. Aretz
Zita E. H. Aretz
ZMZaki Molvi
Zaki Molvi
DSDavid A. Scheinberg
David A. Scheinberg
Exploring the repertoire of peptides presented on major histocompatibility complexes (MHCs) helps identify targets for immunotherapy in many hematologic malignancies. However, there is a paucity of such data for diffuse large B-cell lymphomas (DLBCLs), which might be explained by the profound downregulation of MHC expression in many DLBCLs, and in particular in the enhancer of zeste homolog 2 (EZH2)-mutated subgroup. Epigenetic drug treatment, especially in the context of interferon-γ (IFN-γ), restored MHC expression in DLBCL. In DLBCL, peptides presented on MHCs were identified via mass spectrometry after treatment with tazemetostat or decitabine alone or in combination with IFN-γ. Such treatment synergistically increased the expression of MHC class I surface proteins up to 50-fold and the expression of class II surface proteins up to threefold. Peptides presented on MHCs increased to a similar extent for both class I and class II MHCs. Overall, these treatments restored the diversity of the immunopeptidome to levels described in healthy B cells for 2 of 3 cell lines and allowed the systematic search for new targets for immunotherapy. Consequently, we identified multiple MHC ligands from the regulator of G protein signaling 13 (RGS13) and E2F transcription factor 8 (E2F8) on different MHC alleles, none of which have been described in healthy tissues and therefore represent tumor-specific MHC ligands that are unmasked only after drug treatment. Overall, our results show that EZH2 inhibition in combination with decitabine and IFN-γ can expand the repertoire of MHC ligands presented on DLBCLs by revealing suppressed epitopes, thus allowing the systematic analysis and identification of new potential immunotherapy targets.